Eli Lilly and Company to Acquire Orna Therapeutics in Up to $2.4 Billion Deal

Orna Therapeutics Acquires ReNAgade Therapeutics

May 23, 2024

Biotechnology

Orna Therapeutics has acquired ReNAgade Therapeutics, combining Orna's circular RNA platform with ReNAgade's lipid nanoparticle (LNP) delivery systems and RNA editing capabilities. As part of the deal Amit D. Munshi (former ReNAgade CEO) will succeed Tom Barnes as Orna's CEO, and the combined company will pursue panCAR oncology and autoimmune programs, vaccine collaborations and genetic disease programs supported by substantial financing.

Bristol Myers Squibb to Acquire Orbital Therapeutics in $1.5 Billion Deal

October 11, 2025

Biotechnology

Bristol Myers Squibb (BMS) has entered into an agreement to acquire Orbital Therapeutics, a privately held biotechnology company developing RNA medicines. The $1.5 billion cash deal will give BMS Orbital’s lead candidate OTX-201 and its proprietary RNA platform, supporting BMS’s efforts to advance in vivo CAR T and immunotherapy approaches.

Novo Nordisk to Acquire Dicerna Pharmaceuticals (GalXC RNAi Platform)

November 18, 2021

Biotechnology

Novo Nordisk entered into a definitive agreement to acquire Dicerna Pharmaceuticals for $38.25 per share in cash, valuing the deal at approximately $3.3 billion. The acquisition expands Novo Nordisk’s RNAi research technology platform, building on a 2019 research collaboration using Dicerna’s GalXC technology.

Eli Lilly Acquires Sigilon Therapeutics

June 29, 2023

Biotechnology

Eli Lilly agreed to acquire Sigilon Therapeutics in a cash tender offer valuing the biotech at roughly $34.6 million up front plus contingent value rights that could increase total consideration to about $309.6 million. The acquisition brings Sigilon's encapsulated cell therapy platform (including SIG-002 for type 1 diabetes) into Lilly's diabetes and cell-therapy R&D efforts to accelerate development and potential commercialization.

Gilead Sciences Acquires XinThera

May 9, 2023

Biotechnology

Gilead Sciences has acquired all outstanding shares of XinThera, a San Diego–based private biotechnology company, adding small-molecule oncology and inflammation programs (including PARP1-selective and MK2-targeting assets) to its early pipeline. Financial terms were not disclosed; XinThera was backed by investors including Foresite Capital, OrbiMed and TTM Capital.

IBA Acquires ORA Group to Expand Nuclear Medicine Capabilities

December 19, 2025

Medical Devices

Ion Beam Applications S.A. (IBA) has acquired ORA Group (ORA - Optimized Radiochemical Applications SRL and OOC) to strengthen its leadership in nuclear medicine and radiochemistry. The cash-free, debt-free transaction (total consideration €15–20 million) is financed from IBA’s own funds and existing credit facilities and is immediately accretive to IBA Technologies’ revenue and EBITDA; ORA founder Vincent Tadino will continue with the combined business as CTO.